Ben May Department for Cancer Research, Gordon Center for Integrative Sciences, University of Chicago, Chicago, Illinois, USA.
J Clin Invest. 2010 Dec;120(12):4179-82. doi: 10.1172/JCI45406. Epub 2010 Nov 22.
The retinoblastoma tumor suppressor gene (RB1; encoding RB) is often cited as a gatekeeper, whose inactivation - direct or indirect - is a rate-limiting step for tumor initiation. However, in this issue of the JCI, Sharma et al. show that RB1 loss is a late event in human prostate cancer that is coincident with the emergence of castrate-resistant metastatic disease. This role for RB1 was linked to both E2F transcription factor 1-driven upregulation of the androgen receptor (AR) and increased recruitment of the AR to target gene promoters. This unexpected function for RB1 in late-stage cancer calls upon us to reassess the significance of RB1 inactivation in other cancers in terms of its timing, function in disease etiology, and relevance for cancer therapy.
视网膜母细胞瘤肿瘤抑制基因(RB1;编码 RB)常被认为是一个“守门员”,其失活(直接或间接)是肿瘤发生的限速步骤。然而,在本期《临床研究杂志》中,Sharma 等人表明,RB1 缺失是人类前列腺癌的晚期事件,与去势抵抗性转移性疾病的出现同时发生。RB1 的这一作用与 E2F 转录因子 1 驱动的雄激素受体(AR)上调以及 AR 向靶基因启动子的募集增加有关。RB1 在晚期癌症中的这种意外作用要求我们根据其时间、在疾病发病机制中的功能以及对癌症治疗的相关性,重新评估 RB1 失活在其他癌症中的意义。